A high tumoral DPD expression is associated with 5-FU resistance in CRC; consequently, combining 5-FU with DPD inhibitors (S1PR2 inhibitors or SLR080811) improves efficacy [169,170,171]. This evidence concerns the gene S1PR2 and colorectal carcinoma.